Search

Displaying results 2331 - 2340 of 2817 in total

Drug
MK-0777
go.drugbank.com/drugs/DB12238
Investigational
MK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
Drug
Polatuzumab vedotin
go.drugbank.com/drugs/DB12240
ApprovedInvestigational
consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
Drug
Benzbromarone
go.drugbank.com/drugs/DB12319
ApprovedWithdrawn
Benzbromarone has been used in trials studying the basic science and treatment of Heart Failure, Hyperuricemia, Chronic Kidney Disease, Abnormal Renal Function, and Gout and Asymptomatic Hyperuricemia.
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
Drug
Betrixaban
go.drugbank.com/drugs/DB12364
Approved
Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its fa...
Categories: P-glycoprotein substrates
Drug
Indirubin
go.drugbank.com/drugs/DB12379
Investigational
Indirubin is under investigation in clinical trial NCT01735864 (Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
Drug
Lisofylline
go.drugbank.com/drugs/DB12406
Investigational
Lisofylline has been investigated for the treatment of Type 1 Diabetes Mellitus.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
Drug
Favipiravir
go.drugbank.com/drugs/DB12466
ApprovedInvestigational
Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzyme...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2C8 Inhibitors
Drug
Lucinactant
go.drugbank.com/drugs/DB04897
Approved
It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P).
Drug
DG041
go.drugbank.com/drugs/DB05027
Experimental
DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications. DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of th...
Drug
AN0128
go.drugbank.com/drugs/DB05054
Investigational
Of particular importance is P. acnes and its causal role in acne vulgaris. The rise in antibiotic resistance of P. acnes to standard antibiotics necessitates the development of new treatment agents.